Synagis' Special Status Under Health Care Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
The new Medicaid rebate rules don't bite as deeply for drugs approved exclusively for pediatric use. It turns out that AstraZeneca/MedImmune's Synagis is the only therapy to qualify.
You may also be interested in...
Taking Lumps From Health Care Reform
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate
Acting FDA commissioner Janet Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.
What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate
Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.